Table 1 Characteristics of patients and treatments in all groups

Age

0.391

0.677

 Mean, y

51.68 ± 9.68

52.06 ± 9.90

53.15 ± 10.01

 Range, y

29 ~ 73

25 ~ 82

35 ~ 80

Menopause

1.305

0.521

 Yes

37 (51.4 %)

73 (46.2 %)

32 (54.2 %)

 No

35 (48.6 %)

85 (53.8 %)

27 (45.8 %)

Family History

1.412

0.494

 No

61 (84.7 %)

142 (90.0 %)

53 (89.8 %)

 Cancer (Including BC)

11 (15.3 %)

16 (10.0 %)

6 (10.2 %)

  Quadrant

10.416

0.237

 Areolar

5 (6.9 %)

18 (11.4 %)

8 (13.6 %)

 Outer upper

45 (62.5 %)

83 (52.5 %)

26 (44.1 %)

 Outer lower

17 (23.6 %)

32 (20.3 %)

12 (20.3 %)

 Inner lower

3 (4.2 %)

13 (8.2 %)

9 (15.2 %)

 Inner upper

2 (2.8 %)

12 (7.6 %)

4 (6.8 %)

Operation

6.913

0.141

 Mastectomy

54 (75.0 %)

129 (81.6 %)

42 (71.2 %)

 Tumorectomy

13 (18.1 %)

27 (17.1 %)

14 (23.7 %)

 Breast Reconstruction

5 (6.9 %)

2 (1.3 %)

3 (5.1 %)

Diameter

2.61 ± 1.04

2.50 ± 1.00

2.67 ± 1.00

0.686

0.504

Pathological Types

12.749

0.546

 IDC

47 (65.3 %)

96 (60.8 %)

40 (67.8 %)

 ILC

4 (5.5 %)

13 (8.2 %)

2 (3.4 %)

 DCIS

9 (12.5 %)

24 (15.2 %)

5 (8.5 %)

 Other Types

12 (16.7 %)

25 (15.8 %)

12 (20.3 %)

Histological Grade

7.125

0.129

 I

15 (20.8 %)

43 (27.2 %)

23 (39.0 %)

 II

36 (50.0 %)

64 (40.5 %)

24 (40.7 %)

 III

21 (29.2 %)

51 (32.3 %)

12 (20.3 %)

Node Metastasis

145.677

0.000

 No

72 (100.0 %)

110 (69.6 %)

0 (0.0 %)

 Yes

0 (0.0 %)

48 (30.4 %)

59 (100.0 %)

Cancer Thrombosis

3.034

0.219

 No

47 (65.3 %)

88 (55.7 %)

30 (50.8 %)

 Yes

25 (34.7 %)

70 (44.3 %)

29 (49.2 %)

Estrogen Receptor

16.285

0.000

 Negative

28 (38.9 %)

69 (43.7 %)

42 (71.2 %)

 Positive

44 (61.1 %)

89 (56.3 %)

17 (28.8 %)

Progesterone Receptor

5.770

0.056

 Negative

40 (55.6 %)

88 (55.7 %)

43 (72.9 %)

 Positive

32 (44.4 %)

70 (44.3 %)

16 (27.1 %)

Her2

17.787

0.000

 Negative

62 (86.1 %)

137 (86.7 %)

37 (62.7 %)

 Positive

10 (13.9 %)

21 (13.3 %)

22 (37.3 %)

Ki67

0.010

0.995

 Negative

53 (73.6 %)

116 (73.4 %)

43 (72.9 %)

 Positive

19 (26.4 %)

42 (26.6 %)

16 (27.1 %)

P53

1.497

0.473

 Negative

41 (56.9 %)

77 (48.7 %)

32 (54.2 %)

 Positive

31 (43.1 %)

81 (51.3 %)

27 (45.8 %)

Clinical Stage

92.884

0.000

 0

9 (12.5 %)

14 (8.9 %)

0 (0.0 %)

 I

22 (30.6 %)

49 (31.0 %)

0 (0.0 %)

 IIA

41 (56.9 %)

51 (32.3 %)

16 (27.1 %)

 IIB

0 (0.0 %)

44 (27.8 %)

43 (72.9 %)

Clinicopathological Subtypes

32.593

0.000

 Luminal A

37 (51.4 %)

76 (48.1 %)

16 (27.1 %)

 Luminal B Ki67+

13 (18.1 %)

27 (17.1 %)

7 (11.9 %)

 Luminal B Her2+

6 (8.3 %)

9 (5.7 %)

3 (5.1 %)

 Her2 Over-Expression

4 (5.5 %)

12 (7.6 %)

19 (32.2 %)

 TNBC

12 (16.7 %)

34 (21.5 %)

14 (23.7 %)

Chemotherapy Protocols

84.222

0.000

 No

6 (8.3 %)

15 (9.5 %)

5 (8.5 %)

 CMF

1 (1.4 %)

8 (5.1 %)

0 (0.0 %)

 CAF or AC

20 (27.8 %)

26 (16.5 %)

0 (0.0 %)

 CEF or EC

18 (25.0 %)

36 (22.8 %)

0 (0.0 %)

 TC or TP

23 (31.9 %)

37 (23.3 %)

14 (23.7 %)

 TAC or AC-T

4 (5.6 %)

36 (22.8 %)

40 (67.8 %)

Chemotherapy Cycle

72.874

0.000

 0

6 (8.3 %)

15 (9.5 %)

5 (8.5 %)

 4

19 (26.4 %)

26 (16.5 %)

0 (0.0 %)

 6

43 (59.7 %)

81 (51.2 %)

14 (23.7 %)

 8

4 (5.6 %)

36 (22.8 %)

40 (67.8 %)

Targeted Therapy

4.201

0.122

 No

71 (98.6 %)

152 (96.2 %)

54 (91.5 %)

 Yes

1 (1.4 %)

6 (3.8 %)

5 (8.5 %)

Radiotherapy

26.425

0.000

 No

54 (75.0 %)

100 (63.3 %)

19 (32.2 %)

 Yes

18 (25.0 %)

58 (36.7 %)

40 (67.8 %)

Endocrine Therapy

20.478

0.002

 No

16 (22.1 %)

46 (29.1 %)

33 (55.9 %)

 TAM

22 (30.6 %)

49 (31.0 %)

9 (15.3 %)

 LHRH

12 (16.7 %)

17 (10.8 %)

5 (8.5 %)

 AI

22 (30.6 %)

46 (29.1 %)

12 (20.3 %)